KAF156 + LUM-SDF + Coartem

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Uncomplicated Plasmodium Falciparum Malaria

Conditions

Uncomplicated Plasmodium Falciparum Malaria

Trial Timeline

Feb 16, 2021 → Aug 28, 2024

NCT ID

NCT04546633

About KAF156 + LUM-SDF + Coartem

KAF156 + LUM-SDF + Coartem is a phase 2 stage product being developed by Novartis for Uncomplicated Plasmodium Falciparum Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT04546633. Target conditions include Uncomplicated Plasmodium Falciparum Malaria.

What happened to similar drugs?

1 of 6 similar drugs in Uncomplicated Plasmodium Falciparum Malaria were approved

Approved (1) Terminated (0) Active (5)

✅Co-artemetherNovartisApproved

🔄KLU156 + CoartemNovartisPhase 3

🔄Broncho-munal® + PlaceboSandoz GroupPhase 3

🔄Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg + Phenazopyridine Hydrochloride Tables, USP 200 mgAmneal PharmaceuticalsPhase 3

🔄solithromycin + ceftriaxone + azithromycinAllergy TherapeuticsPhase 3

🔄Sulopenem-Etzadroxil/Probenecid + CiprofloxacinIterum TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04546633	Phase 2	Completed	Feb 16, 2021	Aug 28, 2024	Uncomplicated Plasmodium Falciparum Malaria

Competing Products

13 competing products in Uncomplicated Plasmodium Falciparum Malaria

See all competitors

Product	Company	Stage	Hype Score
ZY19489 + Ferroquine (FQ) + Placebo	Zydus Lifesciences	Phase 1	36
KLU156 + Coartem	Novartis	Phase 3	40
Artemether-lumefantrine (COA566)	Novartis	Phase 2/3	38
INE963	Novartis	Phase 2	35
KAE609 + SoC (Coartem) + KLU156	Novartis	Phase 2	35
KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation	Novartis	Phase 2	35
INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156	Novartis	Phase 2	42
Co-artemether	Novartis	Approved	43
Broncho-munal® + Placebo	Sandoz Group	Phase 3	37
Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg + Phenazopyridine Hydrochloride Tables, USP 200 mg	Amneal Pharmaceuticals	Phase 3	37
Peramivir + Placebo	BioCryst Pharmaceuticals	Phase 2	29
solithromycin + ceftriaxone + azithromycin	Allergy Therapeutics	Phase 3	34
Sulopenem-Etzadroxil/Probenecid + Ciprofloxacin	Iterum Therapeutics	Phase 3	30